Sunvozertinib plus anlotinib for first-line EGFR-mutant lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two oral drugs (sunvozertinib and anlotinib) as a first treatment for advanced lung cancer with certain EGFR mutations plus other gene changes. It aims to see if this combination works better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic non-small cell lung cancer that hasn't been treated yet.
- You have a specific EGFR mutation (like exon 19 deletion, L858R, or T790M) plus another gene change (such as in TP53, PIK3CA, CTNB1, or RB1).
- You are at least 18 years old and in generally good health (ECOG 0 or 1).
- You have at least one tumor that can be measured on a scan.
- If you have brain metastases, they are stable.
- You are not pregnant or breastfeeding, and you agree to use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted pills (sunvozertinib and anlotinib) as a first treatment for people with advanced lung cancer that has a specific EGFR mutation. It aims to see if this combination works better than current standard treatments.
This trial studies an oral targeted medicine (anlotinib) combined with an immunotherapy (checkpoint inhibitor) for lung cancer that did not respond to first-line chemo-immunotherapy. It may help shrink tumors and improve disease control after standard treatment has failed.
This study tests a new targeted therapy, sunvozertinib, for people with a specific type of advanced non-small cell lung cancer that has an EGFR mutation and has stopped responding to previous treatments. It may be an option if you have already tried chemotherapy and an EGFR-targeting drug.
This trial tests a new pill (sunvozertinib) combined with chemotherapy for people with a specific EGFR mutation type of lung cancer whose previous targeted pill stopped working. It aims to see if the combination can shrink tumors or slow the cancer's growth.
This trial tests a drug called sunvozertinib in people with advanced non-small cell lung cancer (NSCLC) that has not been treated yet. It is for those who have certain uncommon changes in the EGFR gene. The drug may shrink tumors or stop them from growing.
This trial tests a new combination of two oral targeted drugs for people with advanced non-small cell lung cancer that has an EGFR mutation. It may help if you have already been treated with a third-generation EGFR pill or if you are starting treatment for the first time.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.